{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:16:12Z","timestamp":1790018172659,"version":"4.0.1"},"reference-count":95,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is a pervasive neurodegenerative disorder characterized by chronic neuroinflammation; current interventions primarily offer symptomatic relief. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, exhibits multi-target therapeutic potential due to its established anti-inflammatory and neuroprotective properties. While growing interest exists, the evidence regarding CBD\u2019s effects on AD-related neuroinflammation has not been robustly consolidated in a quantitative meta-analysis. Therefore, this article reviews the current literature around CBD related to its potential in alleviating neuroinflammation, followed by a meta-analysis of preclinical and clinical studies using random-effects modeling to assess CBD efficacy on neuroinflammation and clinical outcomes in AD. In preclinical AD models, the meta-analysis demonstrated that CBD significantly and consistently reduced key markers of neuroinflammation and reactive gliosis, specifically glial fibrillary acidic protein (GFAP) (p &lt; 0.0001), Interleukin-6 (IL-6), and inducible nitric oxide synthase (iNOS). Effects on other markers, such as tumor necrosis factor-alpha (TNF-\u03b1) and interleukin-1 beta (IL-1\u03b2), were non-significant and heterogeneous. Clinical evidence, though limited by small sample size and heterogeneity, showed a borderline significant benefit favoring CBD for overall behavioral symptoms (p = 0.05), agitation, and caregiver distress. Adverse events were typically mild. We conclude that CBD demonstrates biologically consistent anti-inflammatory efficacy in preclinical AD models. While current clinical data remains insufficient to substantiate efficacy, they suggest promising signals for behavioral control. Determining CBD\u2019s full therapeutic potential in AD necessitates future rigorous, mechanism-driven trials with standardized preparations and biomarker-anchored endpoints.<\/jats:p>","DOI":"10.3390\/ijms262411963","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:13:34Z","timestamp":1765473214000},"page":"11963","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Potential for Cannabidiol on Alzheimer\u2019s Disease-Related Neuroinflammation: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"26","author":[{"given":"Shuo","family":"Wu","sequence":"first","affiliation":[{"name":"UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracia","family":"Rajiah","sequence":"additional","affiliation":[{"name":"UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5203-5609","authenticated-orcid":false,"given":"Afia B.","family":"Ali","sequence":"additional","affiliation":[{"name":"UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., and Karaman, R. (2020). Comprehensive review on Alzheimer\u2019s disease: Causes and treatment. Molecules, 25.","DOI":"10.3390\/molecules25245789"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Elahi, M. (2022). Alzheimer\u2019s Disease, BoD\u2013Books on Demand.","DOI":"10.5772\/intechopen.95246"},{"key":"ref_3","unstructured":"Alzheimer\u2019s Society Research, UK (2024, September 10). The Economic Impact of Dementia. Available online: https:\/\/dementiastatistics.org\/statistics\/the-economic-impact-of-dementia."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.1074\/jbc.275.11.7918","article-title":"\u03b2-Amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1\u03b2- and tumor necrosis factor-\u03b1-dependent, and involves a TNF\u03b1 receptor-associated factor- and NF\u03baB-inducing kinase-dependent signaling mechanism","volume":"275","author":"Akama","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer\u2019s disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1523\/JNEUROSCI.20-02-00558.2000","article-title":"Inflammatory mechanisms in Alzheimer\u2019s disease: Inhibition of \u03b2-amyloid-stimulated proinflammatory responses and neurotoxicity by PPAR\u03b3 agonists","volume":"20","author":"Combs","year":"2000","journal-title":"J. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1073\/pnas.86.19.7611","article-title":"Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease","volume":"86","author":"Griffin","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005072-199503000-00014","article-title":"Interleukin-1 expression in different plaque types in Alzheimer\u2019s disease: Significance in plaque evolution","volume":"54","author":"Griffin","year":"1995","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/nen.0b013e31812503e1","article-title":"Common inflammatory mechanisms in Lewy body disease and Alzheimer disease","volume":"66","author":"Mrak","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/0046-8177(95)90001-2","article-title":"Glial cytokines in Alzheimer\u2019s disease: Review and pathogenic implications","volume":"26","author":"Mrak","year":"1995","journal-title":"Hum. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1017\/S0317167100029863","article-title":"Immune system response in Alzheimer\u2019s disease","volume":"16","author":"McGeer","year":"1989","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0165-0173(95)00011-9","article-title":"The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases","volume":"21","author":"McGeer","year":"1995","journal-title":"Brain Res. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.biocel.2004.07.009","article-title":"The role of inflammation in Alzheimer\u2019s disease","volume":"37","author":"Tuppo","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/pnp.444","article-title":"Evidence for neuroinflammation in Alzheimer\u2019s disease","volume":"20","author":"Walters","year":"2016","journal-title":"Prog. Neurol. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement. Transl. Res. Clin. Interv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1742-2094-8-26","article-title":"Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer\u2019s disease","volume":"8","author":"Grammas","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Meraz-R\u00edos, M.A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hern\u00e1ndez, J., and Campos-Pe\u00f1a, V. (2013). Inflammatory process in Alzheimer\u2019s disease. Front. Integr. Neurosci., 7.","DOI":"10.3389\/fnint.2013.00059"},{"key":"ref_18","first-page":"756357","article-title":"A review: Inflammatory process in Alzheimer\u2032s disease, role of cytokines","volume":"2012","year":"2012","journal-title":"Sci. World J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e13129","DOI":"10.1111\/bpa.13129","article-title":"The fate of interneurons, GABAA receptor sub-types and perineuronal nets in Alzheimer\u2019s disease","volume":"33","author":"Ali","year":"2023","journal-title":"Brain Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/WNL.45.1.51","article-title":"Nonsteroidal anti-inflammatory drugs in Alzheimer\u2019s disease","volume":"45","author":"Rich","year":"1995","journal-title":"Neurology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4065\/73.10.951","article-title":"Nonsteroidal anti-inflammatory drug use and Alzheimer\u2019s disease: A case-control study in Rochester, Minnesota, 1980 through 1984","volume":"73","author":"Beard","year":"1998","journal-title":"Mayo Clin. Proc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1212\/WNL.44.2.227","article-title":"Inverse association of anti-inflammatory treatments and Alzheimer\u2019s disease: Initial results of a co-twin control study","volume":"44","author":"Breitner","year":"1994","journal-title":"Neurology"},{"key":"ref_23","first-page":"141","article-title":"Brain interleukin-1 beta in Alzheimer\u2019s disease and vascular dementia","volume":"16","author":"Cacabelos","year":"1994","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1179573517709278","DOI":"10.1177\/1179573517709278","article-title":"Tumor necrosis factor \u03b1 inhibition for Alzheimer\u2019s disease","volume":"9","author":"Chang","year":"2017","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40035-022-00279-0","article-title":"Brain-derived neurotrophic factor in Alzheimer\u2019s disease and its pharmaceutical potential","volume":"11","author":"Gao","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jalz.2019.09.004","article-title":"Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer\u2019s disease","volume":"16","author":"Elahi","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3233\/JAD-180325","article-title":"Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment","volume":"67","author":"Oeckl","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9982954","DOI":"10.1155\/2021\/9982954","article-title":"Inflammation and Alzheimer\u2019s disease: Mechanisms and therapeutic implications by natural products","volume":"2021","author":"Rather","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ceca.2009.12.010","article-title":"Amyloid \u03b2 oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors","volume":"47","author":"Alberdi","year":"2010","journal-title":"Cell Calcium"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Coles, M., Steiner-Lim, G.Z., and Karl, T. (2022). Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer\u2019s disease. Front. Neurosci., 16.","DOI":"10.3389\/fnins.2022.962922"},{"key":"ref_32","first-page":"357","article-title":"Cannabinoids in epilepsy: Clinical efficacy and pharmacological considerations","volume":"35","year":"2020","journal-title":"Neurologia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"172970","DOI":"10.1016\/j.pbb.2020.172970","article-title":"Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58\/2 transgenic mice","volume":"196","author":"Watt","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/abbs\/gmx073","article-title":"Effects of cannabidiol interactions with Wnt\/\u03b2-catenin pathway and PPAR\u03b3 on oxidative stress and neuroinflammation in Alzheimer\u2019s disease","volume":"49","author":"Lecarpentier","year":"2017","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kopustinskiene, D.M., Masteikova, R., Lazauskas, R., and Bernatoniene, J. (2022). Cannabis sativa L. bioactive compounds and their protective role in oxidative stress and inflammation. Antioxidants, 11.","DOI":"10.3390\/antiox11040660"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"J\u00eetc\u0103, G., \u0150sz, B.E., Vari, C.E., Rusz, C.M., Tero-Vescan, A., and Pu\u0219ca\u0219, A. (2023). Cannabidiol: Bridge between antioxidant effect, cellular protection, and cognitive and physical performance. Antioxidants, 12.","DOI":"10.3390\/antiox12020485"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Meyer, E., Rieder, P., Gobbo, D., Candido, G., Scheller, A., Oliveira, R., and Kirchhoff, F. (2022). Cannabidiol exerts a neuroprotective and glia-balancing effect in the subacute phase of stroke. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112886"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Tadijan, A., Vla\u0161i\u0107, I., Vlaini\u0107, J., \u0110iki\u0107, D., Or\u0161oli\u0107, N., and Jazvin\u0161\u0107ak Jembrek, M. (2022). Intracellular molecular targets and signaling pathways involved in antioxidative and neuroprotective effects of cannabinoids in neurodegenerative conditions. Antioxidants, 11.","DOI":"10.3390\/antiox11102049"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bcpt.13710","article-title":"A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)","volume":"130","author":"Peng","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.freeradbiomed.2011.01.007","article-title":"Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress","volume":"51","author":"Booz","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bcp.2018.08.016","article-title":"Cannabinoid pharmacology\/therapeutics in chronic degenerative disorders affecting the central nervous system","volume":"157","author":"Aymerich","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Cassano, T., Calcagnini, S., Pace, L., De Marco, F., Romano, A., and Gaetani, S. (2017). Cannabinoid receptor 2 signaling in neurodegenerative disorders: From pathogenesis to a promising therapeutic target. Front. Neurosci., 11.","DOI":"10.3389\/fnins.2017.00030"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1038\/emm.2015.100","article-title":"CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson\u2019s disease","volume":"48","author":"Chung","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer\u2019s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation","volume":"25","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/glia.20108","article-title":"Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1\u03b2-stimulated human astrocytes","volume":"49","author":"Sheng","year":"2005","journal-title":"Glia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2012.12.002","article-title":"Endocannabinoid system and mood disorders: Priming a target for new therapies","volume":"138","author":"Micale","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E2229","DOI":"10.1073\/pnas.1219485110","article-title":"Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons","volume":"110","author":"Cristino","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kasatkina, L.A., Rittchen, S., and Sturm, E.M. (2021). Neuroprotective and immunomodulatory action of the endocannabinoid system under neuroinflammation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115431"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2174\/1570159X18666200217140255","article-title":"Endocannabinoid receptors in the CNS: Potential drug targets for the prevention and treatment of neurologic and psychiatric disorders","volume":"18","author":"Estrada","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2174\/1389450117666160112113703","article-title":"The emerging role of the cannabinoid receptor family in peripheral and neuro-immune interactions","volume":"17","author":"Haugh","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB2 receptor and its role as a regulator of inflammation","volume":"73","author":"Turcotte","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/pr.112.006387","article-title":"Chemical probes of endocannabinoid metabolism","volume":"65","author":"Blankman","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/alcalc\/agh110","article-title":"The endocannabinoid system: Physiology and pharmacology","volume":"40","author":"Bilbao","year":"2005","journal-title":"Alcohol Alcohol."},{"key":"ref_55","first-page":"14","article-title":"Getting high on the endocannabinoid system","volume":"2013","author":"Alger","year":"2013","journal-title":"Cerebrum"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/157015907780866910","article-title":"Neuropharmacology of the endocannabinoid signaling system\u2014Molecular mechanisms, biological actions and synaptic plasticity","volume":"5","author":"Basavarajappa","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.phrs.2007.09.002","article-title":"Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders","volume":"56","author":"Bisogno","year":"2007","journal-title":"Pharmacol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.chembiol.2007.11.006","article-title":"A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol","volume":"14","author":"Blankman","year":"2007","journal-title":"Chem. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20270","DOI":"10.1073\/pnas.0909411106","article-title":"Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo","volume":"106","author":"Long","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Papa, A., Pasquini, S., Contri, C., Gemma, S., Campiani, G., Butini, S., Varani, K., and Vincenzi, F. (2022). Polypharmacological approaches for CNS diseases: Focus on endocannabinoid degradation inhibition. Cells, 11.","DOI":"10.3390\/cells11030471"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.brainresbull.2021.06.022","article-title":"The role of endocannabinoid pathway in the neuropathology of Alzheimer\u2019s disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer\u2019s disease?","volume":"174","author":"Bajaj","year":"2021","journal-title":"Brain Res. Bull."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.bjp.0705920","article-title":"Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation","volume":"143","author":"Costa","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/j.pain.0000000000001386","article-title":"Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain","volume":"160","author":"Gregorio","year":"2019","journal-title":"Pain"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"10796","DOI":"10.18632\/aging.202951","article-title":"Potential role of cannabidiol in Parkinson\u2019s disease by targeting the WNT\/\u03b2-catenin pathway, oxidative stress and inflammation","volume":"13","author":"Lecarpentier","year":"2021","journal-title":"Aging"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Sharma, A., and Lee, H.J. (2021). Role of phytoconstituents as PPAR agonists: Implications for neurodegenerative disorders. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121914"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Bielawiec, P., Harasim-Symbor, E., and Chabowski, A. (2020). Phytocannabinoids: Useful drugs for the treatment of obesity? Special focus on cannabidiol. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00114"},{"key":"ref_69","first-page":"607","article-title":"Review of the endocannabinoid system","volume":"6","author":"Lu","year":"2021","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1189\/jlb.3A0115-030RR","article-title":"\u03949-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells","volume":"98","author":"Sido","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","article-title":"Cannabidiol in vivo blunts \u03b2-amyloid induced neuroinflammation by suppressing IL-1\u03b2 and iNOS expression","volume":"151","author":"Esposito","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-140921","article-title":"Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer\u2019s disease transgenic mice","volume":"42","author":"Cheng","year":"2014","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Lana, D., Landucci, E., Mazzantini, C., Magni, G., Pellegrini-Giampietro, D.E., and Giovannini, M.G. (2022). The protective effect of CBD in a model of in vitro ischemia may be mediated by agonism on TRPV2 channel and microglia activation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012144"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/glia.24281","article-title":"Endocannabinoid signaling in microglia","volume":"71","author":"Marinelli","year":"2023","journal-title":"Glia"},{"key":"ref_75","unstructured":"Watt, G., Chesworth, R., Przybyla, M., Garner, B., Ittner, A., Ittner, L.M., and Karl, T. (2020). Effect of 50 mg\/kg CBD on AD-relevant phenotypes of TAU58\/2 transgenic mice. The Therapeutic Potential of the Phytocannabinoid Cannabidiol (CBD) for Alzheimer\u2019s Disease, Western Sydney University."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Aso, E., and Ferrer, I. (2014). Cannabinoids for treatment of Alzheimer\u2019s disease: Moving toward the clinic. Front. Pharmacol., 5.","DOI":"10.3389\/fphar.2014.00037"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00450585","article-title":"Toward drugs derived from cannabis","volume":"65","author":"Mechoulam","year":"1978","journal-title":"Naturwissenschaften"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Hooijmans, C.R., Rovers, M.M., De Vries, R.B., Leenaars, M., Ritskes-Hoitinga, M., and Langendam, M.W. (2014). SYRCLE\u2019s risk of bias tool for animal studies. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-43"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Xiong, Y., and Lim, C.S. (2021). Understanding the modulatory effects of cannabidiol on Alzheimer\u2019s disease. Brain Sci., 11.","DOI":"10.3390\/brainsci11091211"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Yang, S., Du, Y., Zhao, X., Tang, Q., Su, W., Hu, Y., and Yu, P. (2022). Cannabidiol enhances microglial beta-amyloid peptide phagocytosis and clearance via vanilloid family type 2 channel activation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105367"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Esposito, G., Scuderi, C., Valenza, M., Togna, G.I., Latina, V., De Filippis, D., Cipriano, M., Carrat\u00f9, M.R., Iuvone, T., and Steardo, L. (2011). Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028668"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1124\/mol.111.071290","article-title":"Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer\u2019s disease","volume":"79","author":"Reigada","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3233\/JAD-191242","article-title":"Chronic treatment with 50 mg\/kg cannabidiol improves cognition and moderately reduces A\u03b240 levels in 12-month-old male A\u03b2PPswe\/PS1\u0394E9 transgenic mice","volume":"74","author":"Watt","year":"2020","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Chen, L., Sun, Y., Li, J., Liu, S., Ding, H., Wang, G., and Li, X. (2023). Assessing cannabidiol as a therapeutic agent for preventing and alleviating Alzheimer\u2019s disease neurodegeneration. Cells, 12.","DOI":"10.3390\/cells12232672"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12974-024-03204-6","article-title":"Tyrosine phosphorylation and palmitoylation of TRPV2 ion channel tune microglial beta-amyloid peptide phagocytosis","volume":"21","author":"Yang","year":"2024","journal-title":"J. Neuroinflamm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3233\/JAD-210026","article-title":"Cannabidiol ameliorates cognitive function via regulation of IL-33 and TREM2 upregulation in a murine model of Alzheimer\u2019s disease","volume":"80","author":"Khodadadi","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1017\/S1041610224000516","article-title":"Cannabidiol for behavior symptoms in Alzheimer\u2019s disease (CANBiS-AD): A randomized, double-blind, placebo-controlled trial","volume":"36","author":"Velayudhan","year":"2024","journal-title":"Int. Psychogeriatr."},{"key":"ref_89","first-page":"1","article-title":"Oral THC: CBD cannabis extract in main symptoms of Alzheimer disease: Agitation and weight loss","volume":"174","author":"Palmieri","year":"2023","journal-title":"Clin. Ter."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Watt, G., and Karl, T. (2017). In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer\u2019s disease. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00020"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.euroneuro.2018.04.004","article-title":"Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity","volume":"28","author":"Grimm","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Hermush, V., Ore, L., Stern, N., Mizrahi, N., Fried, M., Krivoshey, M., Staghon, E., Lederman, V.E., and Bar-Lev Schleider, L. (2022). Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial. Front. Med., 9.","DOI":"10.3389\/fmed.2022.951889"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbi.2015.03.006","article-title":"Cytokine-producing microglia have an altered beta-amyloid load in aged APP\/PS1 Tg mice","volume":"48","author":"Babcock","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.molmet.2018.03.013","article-title":"Regional differences in brain glucose metabolism determined by imaging mass spectrometry","volume":"12","author":"Kleinridders","year":"2018","journal-title":"Mol. Metab."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"11498","DOI":"10.1021\/acs.jmedchem.3c01029","article-title":"Cannabidiol analogue CIAC001 for the treatment of morphine-induced addiction by targeting PKM2","volume":"66","author":"Jin","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/11963\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:14:38Z","timestamp":1765538078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/11963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":95,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262411963"],"URL":"https:\/\/doi.org\/10.3390\/ijms262411963","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}